<DOC>
	<DOCNO>NCT01797913</DOCNO>
	<brief_summary>ass efficacy safety gemcitabine maintenance treatment advance non-small cell lung cancer</brief_summary>
	<brief_title>The Study Gemcitabine Maintenance Treatment Advanced Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<criteria>18~75 year Patients diagnose histologic , cytologic diagnosis IIIbIV nonsmall cell lung cancer patient acceptted combination chemotherapy base platinum 4 course , SD OR PR , CR patient accept 6 course combination chemotherapy . 3~8 week patient complete first line chemotherapy ( include radiotherapy ) Ecog02 Expected life time longer 3 monthes Normal laboratory value : leucocyte ≥ 4×109/L neutrophil ≥ 1.5×109/L platelet ≥ 100×109/L Hemoglobin ≥ 10g/L ALT AST ≤ 2.5×ULN ( ≤ 5×ULN liver metastasis ) Signed write informed consent Patients use drug accord protocol Uncontrolled infection Bacterial virus fungal Patients malignant tumor Uncontrolled brain metastasis Female patient pregnant lactation period , patient without contracep</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>